Related Experiment Video

Updated: Jun 13, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

New therapies in soft tissue sarcoma

Bruno Vincenzi1, Anna Maria Frezza, Daniele Santini

  • 1University Campus Bio-Medico, Medical Oncology, Via Alvaro del Portillo, 200, 00128, Rome, Italy. b.vincenzi@unicampus.it

Expert Opinion on Emerging Drugs
|May 15, 2010
PubMed
Abstract

Insights

New targeted therapies show promise for improving survival rates in soft tissue sarcoma patients. Clinical trials are crucial for advancing treatment and managing this aggressive cancer.

Area of Science:

  • Oncology
  • Sarcoma Research
  • Clinical Therapeutics

Background:

  • Soft tissue sarcomas are rare mesenchymal tumors, comprising less than 1% of adult cancers.
  • Current treatments (surgery, radiotherapy, chemotherapy) yield a 5-year survival rate of only 50-60% for soft tissue sarcoma.
  • Locally advanced and metastatic soft tissue sarcomas present significant treatment challenges.

Purpose of the Study:

  • To review novel molecules under clinical evaluation for soft tissue sarcoma treatment.
  • To analyze the mechanism of action and biological rationale for new targeted therapies.
  • To report safety and efficacy data for emerging soft tissue sarcoma treatments up to 2009.

Main Methods:

  • Literature review of clinical trials and research on soft tissue sarcoma.
  • Analysis of drug mechanisms targeting sarcoma tumorigenesis.
  • Compilation of safety and efficacy data for new therapeutic agents.

Main Results:

  • Summary of current standard treatments for soft tissue sarcoma.
  • Detailed analysis of the development of new targeted therapies.
  • Overview of the state-of-the-art in soft tissue sarcoma drug development.

Conclusions:

  • New biological therapies targeting key points in soft tissue sarcoma tumorigenesis offer improved prognosis.
  • Participation in clinical trials is the optimal management strategy for soft tissue sarcoma patients.
  • Encouraging enrollment in clinical trials is vital for advancing soft tissue sarcoma care.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.